{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:28:11Z","timestamp":1791584891085,"version":"4.3.4"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) represents an immunologically \u201ccold\u201d and metabolically suppressive tumor characterized by profound T-cell exhaustion, hypoxia-induced adenosinergic signaling, and resistance to checkpoint blockade. Converging evidence identifies lymphocyte-activation gene 3 (LAG-3) and the CD39\/CD73 ectonucleotidase cascade as cooperative regulators of immune dysfunction within the GBM microenvironment. LAG-3 attenuates TCR\/CD3 signaling and disrupts mitochondrial oxidative phosphorylation, diminishing effector T-cell persistence. Concurrently, CD39\/CD73-mediated ATP hydrolysis elevates adenosine levels, activating A\u2082A receptors that inhibit glycolysis, suppress IFN-\u03b3, and promote Treg and M2 macrophage polarization. Spatial and single-cell omics reveal co-localization of LAG-3\u207a exhausted T cells with CD73\u207a stromal and myeloid niches, suggesting a reciprocal immunometabolic feedback loop reinforcing exhaustion. This review elucidates the molecular crosstalk between LAG-3 signaling and the adenosine pathway, emphasizing key metabolic regulators including AMPK, mTOR, and HIF-1\u03b1. It further evaluates therapeutic strategies combining LAG-3 or PD-1 blockade with adenosine receptor antagonists or CD73 inhibitors to restore T-cell bioenergetics and antitumor activity. By integrating mechanistic immunometabolism with translational insights, this review establishes a dual-pathway framework of checkpoint synergy underlying resistance in GBM and proposes rational combination immunotherapies to reverse metabolic and immune exhaustion.<\/jats:p>","DOI":"10.1186\/s43046-026-00361-y","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:02:05Z","timestamp":1781478125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune checkpoint crosstalk between LAG-3 and CD39\/CD73 in glioblastoma: dual-pathway regulation of metabolic exhaustion and therapeutic reversal strategies"],"prefix":"10.1186","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6038-7337","authenticated-orcid":false,"given":"Arpita","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"2","key":"361_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.36401\/JIPO-23-34","volume":"7","author":"MH Ser","year":"2024","unstructured":"Ser MH, Webb MJ, Sener U, Campian JL. Immune checkpoint inhibitors and glioblastoma: a review on current state and future directions. J Immunother Precis Oncol. 2024;7(2):97\u2013110. https:\/\/doi.org\/10.36401\/JIPO-23-34.","journal-title":"J Immunother Precis Oncol"},{"issue":"24","key":"361_CR2","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.3390\/cancers16244148","volume":"16","author":"AB Baskaran","year":"2024","unstructured":"Baskaran AB, Kozel OA, Venkatesh O, Wainwright DA, Sonabend AM, Heimberger AB, Lukas RV. Immune checkpoint inhibitors in glioblastoma IDHwt treatment: a systematic review. Cancers (Basel). 2024;16(24):4148. https:\/\/doi.org\/10.3390\/cancers16244148.","journal-title":"Cancers (Basel)"},{"issue":"1\u20132","key":"361_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","volume":"176","author":"J Wang","year":"2019","unstructured":"Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176(1\u20132):334\u2013e34712. https:\/\/doi.org\/10.1016\/j.cell.2018.11.010.","journal-title":"Cell"},{"issue":"1","key":"361_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y, Targeting. LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"361_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","volume":"3","author":"T Kouo","year":"2015","unstructured":"Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, Jaffee E. Galectin-3 shapes antitumor immune responses by suppressing CD8\u207a T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015;3(4):412\u201323. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0150.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"361_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121\u201344. https:\/\/doi.org\/10.1111\/imr.12528.","journal-title":"Immunol Rev"},{"issue":"4","key":"361_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/cells14040309","volume":"14","author":"L Lin","year":"2025","unstructured":"Lin L, Roccuzzo G, Yakymiv Y, Marchisio S, Ortolan E, Funaro A, Senetta R, Pala V, Bagot M, de Masson A, Battistella M, Guenova E, Ribero S, Quaglino P. The CD39\/CD73\/adenosine and NAD\/CD38\/CD203a\/CD73 axis in cutaneous T-cell lymphomas. Cells. 2025;14(4):309. https:\/\/doi.org\/10.3390\/cells14040309.","journal-title":"Cells"},{"key":"361_CR8","doi-asserted-by":"publisher","first-page":"956090","DOI":"10.3389\/fimmu.2022.956090","volume":"13","author":"JL Huo","year":"2022","unstructured":"Huo JL, Wang YT, Fu WJ, Lu N, Liu ZS. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022;13:956090. https:\/\/doi.org\/10.3389\/fimmu.2022.956090. eCollection 2022.","journal-title":"Front Immunol"},{"issue":"5","key":"361_CR9","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/21645515.2020.1782692","volume":"16","author":"T Yang","year":"2020","unstructured":"Yang T, Kong Z, Ma W. PD-1\/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. Hum Vaccin Immunother. 2020;16(5):1009\u201317. https:\/\/doi.org\/10.1080\/21645515.2020.1782692.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"361_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13046-024-02968-2","volume":"43","author":"G Scafetta","year":"2024","unstructured":"Scafetta G, D\u2019Alessandria C, Bartolazzi A. Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape. J Exp Clin Cancer Res. 2024;43(1):41. https:\/\/doi.org\/10.1186\/s13046-024-02968-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"361_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40364-023-00500-w","volume":"11","author":"Y Liu","year":"2023","unstructured":"Liu Y, Li Z, Lu L, et al. Review immune response of targeting CD39 in cancer. Biomark Res. 2023;11:63. https:\/\/doi.org\/10.1186\/s40364-023-00500-w.","journal-title":"Biomark Res"},{"issue":"17","key":"361_CR12","doi-asserted-by":"publisher","first-page":"9958","DOI":"10.3390\/ijms23179958","volume":"23","author":"N Sauer","year":"2022","unstructured":"Sauer N, Szlasa W, Jonderko L, O\u015bliz\u0142o M, Kunachowicz D, Kulbacka J, Kar\u0142owicz-Bodalska K. LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors. Int J Mol Sci. 2022;23(17):9958. https:\/\/doi.org\/10.3390\/ijms23179958.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"361_CR13","doi-asserted-by":"publisher","first-page":"vdae174","DOI":"10.1093\/noajnl\/vdae174","volume":"6","author":"E Schonfeld","year":"2024","unstructured":"Schonfeld E, Choi J, Tran A, Kim LH, Lim M. The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: a systematic review. Neurooncol Adv. 2024;6(1):vdae174. https:\/\/doi.org\/10.1093\/noajnl\/vdae174.","journal-title":"Neurooncol Adv"},{"key":"361_CR14","doi-asserted-by":"publisher","first-page":"20418","DOI":"10.1039\/D5RA02235E","volume":"15","author":"P Maity","year":"2025","unstructured":"Maity P, Ganguly S, Deb PK. Therapeutic potential of adenosine receptor modulators in cancer treatment. RSC Adv. 2025;15:20418\u201345. https:\/\/doi.org\/10.1039\/D5RA02235E.","journal-title":"RSC Adv"},{"issue":"1","key":"361_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1186\/s40001-023-01583-9","volume":"28","author":"J Peng","year":"2023","unstructured":"Peng J, Du Z, Sun Y, Zhou Z. A combined analysis of multi-omics data reveals the prognostic values and immunotherapy response of LAG3 in human cancers. Eur J Med Res. 2023;28(1):604. https:\/\/doi.org\/10.1186\/s40001-023-01583-9.","journal-title":"Eur J Med Res"},{"issue":"3","key":"361_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41590-022-01166-6","volume":"23","author":"T Maruhashi","year":"2022","unstructured":"Maruhashi T, Okazaki IM, Sugiura D, Takahashi S, Maeda TK, Shimizu K, et al. LAG-3 inhibits the activation of CD4\u207a T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat Immunol. 2022;23(3):386\u201398. https:\/\/doi.org\/10.1038\/s41590-022-01166-6.","journal-title":"Nat Immunol"},{"issue":"5","key":"361_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","volume":"23","author":"C Guy","year":"2022","unstructured":"Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, Zhang H, Kriwacki R, Bruchez MP, Watkins SC, Workman CJ, Vignali DAA. LAG-3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat Immunol. 2022;23(5):757\u201367. https:\/\/doi.org\/10.1038\/s41590-022-01176-4.","journal-title":"Nat Immunol"},{"issue":"25","key":"361_CR18","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo H, Chen J, Gonz\u00e1lez-Avalos E, Samaniego-Castruita D, Das A, Wang YH, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8\u207a T cell exhaustion. Proc Natl Acad Sci U S A. 2019;116(25):12410\u20135. https:\/\/doi.org\/10.1073\/pnas.1905675116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"361_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez GJ, Pereira RM, \u00c4ij\u00f6 T, Kim EY, Marangoni F, Pipkin ME, et al. The transcription factor NFAT promotes exhaustion of activated CD8\u207a T cells. Immunity. 2015;42(2):265\u201378. https:\/\/doi.org\/10.1016\/j.immuni.2015.01.006.","journal-title":"Immunity"},{"issue":"16","key":"361_CR20","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","volume":"24","author":"KI Woroniecka","year":"2018","unstructured":"Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. T-cell dysfunction in glioblastoma: applying a new framework. Clin Cancer Res. 2018;24(16):3792\u2013802. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0047.","journal-title":"Clin Cancer Res"},{"key":"361_CR21","doi-asserted-by":"publisher","first-page":"1561388","DOI":"10.3389\/fimmu.2025.1561388","volume":"16","author":"Y Fu","year":"2025","unstructured":"Fu Y, Yi Y, Shao Y, Jiang J, Deng Q. Single-cell and spatial transcriptomic insights into glioma cellular heterogeneity and metabolic adaptations. Front Immunol. 2025;16:1561388. https:\/\/doi.org\/10.3389\/fimmu.2025.1561388.","journal-title":"Front Immunol"},{"issue":"9","key":"361_CR22","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1093\/neuonc\/noaf099","volume":"27","author":"CY Hung","year":"2025","unstructured":"Hung CY, Kang EY, Jacek K, Yu C, Zhang X, Zhu Y, et al. Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD-1 immune checkpoint blockade. Neuro Oncol. 2025;27(9):2296\u2013312. https:\/\/doi.org\/10.1093\/neuonc\/noaf099.","journal-title":"Neuro Oncol"},{"issue":"6","key":"361_CR23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-23-0913","volume":"14","author":"AZ Wang","year":"2024","unstructured":"Wang AZ, Mashimo BL, Schaettler MO, Sherpa ND, Leavitt LA, Livingstone AJ, et al. Glioblastoma-infiltrating CD8\u207a T cells are predominantly a clonally expanded GZMK\u207a effector population. Cancer Discov. 2024;14(6):1106\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0913.","journal-title":"Cancer Discov"},{"issue":"1","key":"361_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DAA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396. https:\/\/doi.org\/10.1111\/imr.12519.","journal-title":"Immunol Rev"},{"key":"361_CR25","doi-asserted-by":"publisher","first-page":"101305","DOI":"10.1016\/j.smim.2019.101305","volume":"42","author":"E Ruffo","year":"2019","unstructured":"Ruffo E, Wu R, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin Immunol. 2019;42:101305. https:\/\/doi.org\/10.1016\/j.smim.2019.101305.","journal-title":"Semin Immunol"},{"issue":"30","key":"361_CR26","doi-asserted-by":"publisher","first-page":"49178","DOI":"10.18632\/oncotarget.16544","volume":"8","author":"DH Heiland","year":"2017","unstructured":"Heiland DH, W\u00f6rner J, Haaker JG, Delev D, Pompe N, Mercas B, et al. The integrative metabolomic-transcriptomic landscape of glioblastoma multiforme. Oncotarget. 2017;8(30):49178\u201390. https:\/\/doi.org\/10.18632\/oncotarget.16544.","journal-title":"Oncotarget"},{"issue":"12","key":"361_CR27","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1002\/ijc.31661","volume":"143","author":"S Harris-Bookman","year":"2018","unstructured":"Harris-Bookman S, Mathios D, Martin AM, Xia Y, Kim E, Xu H, Belcaid Z, Polanczyk M, Barberi T, Theodros D, Kim J, Taube JM, Burger PC, Selby M, Taitt C, Korman A, Ye X, Drake CG, Brem H. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. Int J Cancer. 2018;143(12):3201\u20138. https:\/\/doi.org\/10.1002\/ijc.31661.","journal-title":"Int J Cancer"},{"issue":"11","key":"361_CR28","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","volume":"29","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, et al. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023;29(11):2814\u201324. https:\/\/doi.org\/10.1038\/s41591-023-02593-0.","journal-title":"Nat Med"},{"key":"361_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12943-025-02426-3","volume":"24","author":"J Le","year":"2025","unstructured":"Le J, Dian Y, Zhao D, Guo Z, Luo Z, Chen X, Zeng F, Deng G. Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment. Mol Cancer. 2025;24:221. https:\/\/doi.org\/10.1186\/s12943-025-02426-3.","journal-title":"Mol Cancer"},{"issue":"18","key":"361_CR30","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/cells13181574","volume":"13","author":"AI Cortes Ballen","year":"2024","unstructured":"Cortes Ballen AI, Amosu M, Ravinder S, Chan J, Derin E, Slika H, Tyler B. Metabolic reprogramming in glioblastoma multiforme: a review of pathways and therapeutic targets. Cells. 2024;13(18):1574. https:\/\/doi.org\/10.3390\/cells13181574.","journal-title":"Cells"},{"key":"361_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia C, Yin S, Fu L, et al. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023;22:44. https:\/\/doi.org\/10.1186\/s12943-023-01733-x.","journal-title":"Mol Cancer"},{"key":"361_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fimmu.2014.00304","volume":"5","author":"A Ohta","year":"2014","unstructured":"Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol. 2014;5:304. https:\/\/doi.org\/10.3389\/fimmu.2014.00304.","journal-title":"Front Immunol"},{"issue":"12","key":"361_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrc.2017.86","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17(12):709\u201324. https:\/\/doi.org\/10.1038\/nrc.2017.86.","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"361_CR34","doi-asserted-by":"publisher","first-page":"12608","DOI":"10.3390\/ijms222212608","volume":"22","author":"M Dom\u00e8nech","year":"2021","unstructured":"Dom\u00e8nech M, et al. Hypoxia: The Cornerstone of Glioblastoma. Int J Mol Sci. 2021;22(22):12608. https:\/\/doi.org\/10.3390\/ijms222212608.","journal-title":"Int J Mol Sci"},{"key":"361_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.coph.2016.06.009","volume":"29","author":"SM Hatfield","year":"2016","unstructured":"Hatfield SM, Sitkovsky M. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1\u03b1 driven immunosuppression and improve immunotherapies of cancer. Curr Opin Pharmacol. 2016;29:90\u20136. https:\/\/doi.org\/10.1016\/j.coph.2016.06.009.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"361_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.it.2012.02.009","volume":"33","author":"PA Beavis","year":"2012","unstructured":"Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 2012;33(5):231\u20137. https:\/\/doi.org\/10.1016\/j.it.2012.02.009.","journal-title":"Trends Immunol"},{"issue":"1","key":"361_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12943-025-02267-0","volume":"24","author":"A Pouyan","year":"2025","unstructured":"Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A, Mokhtari K, Shahpasand K, Farahani N, Emami T, Entezari M, Taheriazam A, Hushmandi K, Hashemi M. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025;24(1):67. https:\/\/doi.org\/10.1186\/s12943-025-02267-0.","journal-title":"Mol Cancer"},{"issue":"7","key":"361_CR38","doi-asserted-by":"publisher","first-page":"e011652","DOI":"10.1136\/jitc-2025-011652","volume":"13","author":"D Davar","year":"2025","unstructured":"Davar D, Carrizosa Anderson A, Diaz-Padilla I. Therapeutic potential of targeting LAG-3 in cancer. J Immunother Cancer. 2025;13(7):e011652. https:\/\/doi.org\/10.1136\/jitc-2025-011652.","journal-title":"J Immunother Cancer"},{"key":"361_CR39","doi-asserted-by":"publisher","first-page":"1661327","DOI":"10.3389\/fimmu.2025.1661327","volume":"16","author":"X Lang","year":"2025","unstructured":"Lang X, Zhang W, Liu Y, et al. Targeting the neuroimmune axis in glioblastoma. Front Immunol. 2025;16:1661327. https:\/\/doi.org\/10.3389\/fimmu.2025.1661327.","journal-title":"Front Immunol"},{"key":"361_CR40","doi-asserted-by":"publisher","first-page":"1584688","DOI":"10.3389\/fphar.2025.1584688","volume":"16","author":"M Fu","year":"2025","unstructured":"Fu M, Xue B, Miao X, Gao Z. Overcoming immunotherapy resistance in glioblastoma: challenges and emerging strategies. Front Pharmacol. 2025;16:1584688. https:\/\/doi.org\/10.3389\/fphar.2025.1584688.","journal-title":"Front Pharmacol"},{"key":"361_CR41","doi-asserted-by":"publisher","first-page":"1639521","DOI":"10.3389\/fimmu.2025.1639521","volume":"16","author":"O Musatova","year":"2025","unstructured":"Musatova O, Kumar V, Vinogradov K, Rubtsov Y. Immune checkpoints in immune response to glioma: two sides of the same coin. Front Immunol. 2025;16:1639521. https:\/\/doi.org\/10.3389\/fimmu.2025.1639521.","journal-title":"Front Immunol"},{"issue":"1","key":"361_CR42","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","volume":"13","author":"S Coy","year":"2022","unstructured":"Coy S, Wang S, Stopka SA, Lin J-R, Yapp C, Ritch CC, Salhi L, Baker GJ, Rashid R, Baquer G. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nat Commun. 2022;13(1):4814. https:\/\/doi.org\/10.1038\/s41467-022-32430-w.","journal-title":"Nat Commun"},{"issue":"4","key":"361_CR43","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.trecan.2022.12.008","volume":"9","author":"MB Watowich","year":"2023","unstructured":"Watowich MB, Gilbert MR, Larion M. T cell exhaustion in malignant gliomas. Trends Cancer. 2023;9(4):270\u201392. https:\/\/doi.org\/10.1016\/j.trecan.2022.12.008.","journal-title":"Trends Cancer"},{"key":"361_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fcell.2020.00017","volume":"8","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T Cell Dysfunction and Exhaustion in Cancer. Front Cell Dev Biol. 2020;8:17. https:\/\/doi.org\/10.3389\/fcell.2020.00017.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"361_CR45","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/cancers17111881","volume":"17","author":"R Medikonda","year":"2025","unstructured":"Medikonda R, Abikenari M, Schonfeld E, Lim M. The Metabolic Orchestration of Immune Evasion in Glioblastoma: From Molecular Perspectives to Therapeutic Vulnerabilities. Cancers (Basel). 2025;17(11):1881. https:\/\/doi.org\/10.3390\/cancers17111881.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"361_CR46","doi-asserted-by":"publisher","first-page":"6688","DOI":"10.3390\/ijms24076688","volume":"24","author":"S Rafii","year":"2023","unstructured":"Rafii S, Ghouzlani A, Naji O, Ait Ssi S, Kandoussi S, Lakhdar A, Badou A. A2AR as a Prognostic Marker and a Potential Immunotherapy Target in Human Glioma. Int J Mol Sci. 2023;24(7):6688. https:\/\/doi.org\/10.3390\/ijms24076688.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"361_CR47","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/cells13110924","volume":"13","author":"O Franzese","year":"2024","unstructured":"Franzese O, et al. Apoptosis, a Metabolic Head-to-Head between Tumor and Immune Cells. Cells. 2024;13(11):924. https:\/\/doi.org\/10.3390\/cells13110924.","journal-title":"Cells"},{"key":"361_CR48","doi-asserted-by":"publisher","first-page":"1501613","DOI":"10.3389\/fimmu.2024.1501613","volume":"15","author":"K Ren","year":"2024","unstructured":"Ren K, Hamdy H, Meyiah A, Elkord E. Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials. Front Immunol. 2024;15:1501613. https:\/\/doi.org\/10.3389\/fimmu.2024.1501613.","journal-title":"Front Immunol"},{"key":"361_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fimmu.2019.00162","volume":"10","author":"C Sorrentino","year":"2019","unstructured":"Sorrentino C, et al. Adenosine A2A receptor stimulation inhibits TCR-induced Notch1 signaling in CD8\u2009+\u2009T cells. Front Immunol. 2019;10:162. https:\/\/doi.org\/10.3389\/fimmu.2019.00162.","journal-title":"Front Immunol"},{"issue":"8","key":"361_CR50","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41590-023-01529-7","volume":"24","author":"VH Wu","year":"2023","unstructured":"Wu VH, Yung BS, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel AT, Song MJ, Pagadala MS. The GPCR-G\u03b1s-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure. Nat Immunol. 2023;24(8):1318\u201330. https:\/\/doi.org\/10.1038\/s41590-023-01529-7.","journal-title":"Nat Immunol"},{"key":"361_CR51","doi-asserted-by":"publisher","first-page":"1201632","DOI":"10.3389\/fimmu.2023.1201632","volume":"14","author":"B Zohair","year":"2023","unstructured":"Zohair B, et al. The immune checkpoint adenosine 2A receptor is associated with T cell dysfunction in cancer. Front Immunol. 2023;14:1201632. https:\/\/doi.org\/10.3389\/fimmu.2023.1201632.","journal-title":"Front Immunol"},{"key":"361_CR52","doi-asserted-by":"publisher","first-page":"RP92678","DOI":"10.7554\/eLife.92678","volume":"12","author":"P Schmassmann","year":"2023","unstructured":"Schmassmann P, Roux J, Dettling S, Hogan S, Shekarian T, Martins TA, Ritz M-F, Herter S, Bacac M, Hutter G. Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation. eLife. 2023;12:RP92678. https:\/\/doi.org\/10.7554\/eLife.92678.","journal-title":"eLife"},{"issue":"1","key":"361_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-025-00784-0","volume":"13","author":"Y Yang","year":"2025","unstructured":"Yang Y, et al. The progress and prospects of targeting the adenosine pathway in cancer immunotherapy. Biomark Res. 2025;13(1):7. https:\/\/doi.org\/10.1186\/s40364-025-00784-0.","journal-title":"Biomark Res"},{"issue":"7","key":"361_CR54","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41423-020-0365-3","volume":"18","author":"N Dumauthioz","year":"2021","unstructured":"Dumauthioz N, Tschumi B, Wenes M, Marti B, Wang H, Franco F, Li W, Lopez-Mejia IC, Fajas L, Ho PC, Donda A, Romero P, Zhang L. Enforced PGC-1\u03b1 expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol Immunol. 2021;18(7):1761\u201371. https:\/\/doi.org\/10.1038\/s41423-020-0365-3.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"361_CR55","doi-asserted-by":"publisher","first-page":"920","DOI":"10.18632\/oncotarget.26643","volume":"10","author":"S Lehtipuro","year":"2019","unstructured":"Lehtipuro S, Nykter M, Granberg KJ. Modes of immunosuppression in glioblastoma microenvironment. Oncotarget. 2019;10(9):920\u20131. https:\/\/doi.org\/10.18632\/oncotarget.26643.","journal-title":"Oncotarget"},{"issue":"3","key":"361_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell. 2016;30(3):391\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2016.06.025.","journal-title":"Cancer Cell"},{"issue":"15","key":"361_CR57","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.3390\/molecules29153501","volume":"29","author":"KN Venugopala","year":"2024","unstructured":"Venugopala KN, Buccioni M. Current understanding of the role of adenosine receptors in cancer. Molecules. 2024;29(15):3501. https:\/\/doi.org\/10.3390\/molecules29153501.","journal-title":"Molecules"},{"issue":"8","key":"361_CR58","doi-asserted-by":"publisher","first-page":"e006457","DOI":"10.1136\/jitc-2022-006457","volume":"11","author":"V Graziano","year":"2023","unstructured":"Graziano V, Dannhorn A, Hulme H, Williamson K, Buckley H, Karim SA, et al. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. J Immunother Cancer. 2023;11(8):e006457. https:\/\/doi.org\/10.1136\/jitc-2022-006457.","journal-title":"J Immunother Cancer"},{"issue":"19","key":"361_CR59","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2217\/fon-2023-0871","volume":"20","author":"N Kaplinsky","year":"2024","unstructured":"Kaplinsky N, Williams K, Watkins D, Adams M, Stanbery L, Nemunaitis J. Regulatory role of CD39 and CD73 in tumor immunity. Future Oncol. 2024;20(19):1367\u201380. https:\/\/doi.org\/10.2217\/fon-2023-0871.","journal-title":"Future Oncol"},{"issue":"9","key":"361_CR60","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00262-020-02569-w","volume":"69","author":"JH Azambuja","year":"2020","unstructured":"Azambuja JH, Schuh RS, Michels LR, Iser IC, Beckenkamp LR, Roliano GG, et al. Blockade of CD73 delays glioblastoma growth by modulating the immune environment. Cancer Immunol Immunother. 2020;69(9):1801\u201312. https:\/\/doi.org\/10.1007\/s00262-020-02569-w.","journal-title":"Cancer Immunol Immunother"},{"key":"361_CR61","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.06.674490","author":"M Wang","year":"2025","unstructured":"Wang M, Fu Y, Bom S, et al. Dual checkpoint blockade of glioblastoma with Anti-PD-1 and Anti-LAG-3 promotes expansion of tumor-reactive T cell clones along a unique pathway of differentiation. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.09.06.674490.","journal-title":"bioRxiv"},{"issue":"1","key":"361_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"issue":"10","key":"361_CR63","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-22-0057","volume":"10","author":"K Thudium","year":"2022","unstructured":"Thudium K, Selby M, Zorn JA, Rak G, Wang X-T, Bunch RT, et al. Preclinical characterization of relatlimab, a human LAG-3-blocking antibody, alone or in combination with nivolumab. Cancer Immunol Res. 2022;10(10):1175\u201389. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0057.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"361_CR64","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03468-7","volume":"72","author":"JC Bendell","year":"2023","unstructured":"Bendell JC, LoRusso PM, Overman M, Noonan AM, Kim DW, Strickler JH, et al. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2023;72(11):2443\u201358. https:\/\/doi.org\/10.1007\/s00262-023-03468-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"361_CR65","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3390\/pharmaceutics16091127","volume":"16","author":"T-Y Chen","year":"2024","unstructured":"Chen T-Y, Chang Y-C, Yu C-Y, Sung W-W. Targeting the adenosine A2A receptor as a novel therapeutic approach for renal cell carcinoma: mechanisms and clinical trial review. Pharmaceutics. 2024;16(9):1127. https:\/\/doi.org\/10.3390\/pharmaceutics16091127.","journal-title":"Pharmaceutics"},{"key":"361_CR66","doi-asserted-by":"publisher","first-page":"1584688","DOI":"10.3389\/fphar.2025.1584688","volume":"16","author":"M Fu","year":"2025","unstructured":"Fu M, Xue B, Miao X, Gao Z. Overcoming immunotherapy resistance in glioblastoma: challenges and emerging strategies. Front Pharmacol. 2025;16:1584688. https:\/\/doi.org\/10.3389\/fphar.2025.1584688.","journal-title":"Front Pharmacol"},{"key":"361_CR67","doi-asserted-by":"publisher","first-page":"638037","DOI":"10.3389\/fcell.2021.638037","volume":"9","author":"P Brice\u00f1o","year":"2021","unstructured":"Brice\u00f1o P, Rivas-Ya\u00f1ez E, Rosemblatt MV, Parra-Tello B, Far\u00edas P, Vargas L, et al. CD73 ectonucleotidase restrains CD8\u207a T cell metabolic fitness and anti-tumoral activity. Front Cell Dev Biol. 2021;9:638037. https:\/\/doi.org\/10.3389\/fcell.2021.638037.","journal-title":"Front Cell Dev Biol"},{"key":"361_CR68","doi-asserted-by":"publisher","first-page":"662064","DOI":"10.3389\/fnins.2021.662064","volume":"15","author":"L Maggs","year":"2021","unstructured":"Maggs L, et al. CAR T cell-based immunotherapy for the treatment of glioblastoma. Front Neurosci. 2021;15:662064. https:\/\/doi.org\/10.3389\/fnins.2021.662064.","journal-title":"Front Neurosci"},{"key":"361_CR69","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41420-024-02171-4","volume":"10","author":"R An","year":"2024","unstructured":"An R, Wu C, Tang C, Zhang C, Han F, Xu Z, et al. Blockade of CD73 potentiates radiotherapy antitumor immunity and abscopal effects via STING pathway. Cell Death Discov. 2024;10:404. https:\/\/doi.org\/10.1038\/s41420-024-02171-4.","journal-title":"Cell Death Discov"},{"issue":"1","key":"361_CR70","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41392-023-01683-2","volume":"8","author":"D Xie","year":"2023","unstructured":"Xie D, Tian Y, Hu D, Wang Y, Yang Y, Zhou B, et al. Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy. Signal Transduct Target Ther. 2023;8(1):436. https:\/\/doi.org\/10.1038\/s41392-023-01683-2.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"361_CR71","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13(1):66. https:\/\/doi.org\/10.1186\/s40164-024-00535-1.","journal-title":"Exp Hematol Oncol"},{"issue":"Pt 3","key":"361_CR72","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.semcancer.2022.02.012","volume":"86","author":"I Preddy","year":"2022","unstructured":"Preddy I, Nandoliya K, Miska J, Ahmed AU, Checkpoint. Inspecting the barriers in glioblastoma immunotherapies. Semin Cancer Biol. 2022;86(Pt 3):473\u201381. https:\/\/doi.org\/10.1016\/j.semcancer.2022.02.012.","journal-title":"Semin Cancer Biol"},{"key":"361_CR73","doi-asserted-by":"publisher","first-page":"110786","DOI":"10.1016\/j.jocn.2024.110786","volume":"128","author":"SF Maroufi","year":"2024","unstructured":"Maroufi SF, Fallahi MS, Maroufi SP, Sheehan JP. Focused ultrasound blood-brain barrier disruption in high-grade gliomas: Scoping review of clinical studies. J Clin Neurosci. 2024;128:110786. https:\/\/doi.org\/10.1016\/j.jocn.2024.110786.","journal-title":"J Clin Neurosci"},{"key":"361_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.actbio.2025.01.050","volume":"194","author":"Y Xiong","year":"2025","unstructured":"Xiong Y, Sun M, Yang Q, Zhang W, Song A, Tan Y, et al. Nanoparticle-based drug delivery systems to modulate tumor immune response for glioblastoma treatment. Acta Biomater. 2025;194:38\u201357. https:\/\/doi.org\/10.1016\/j.actbio.2025.01.050.","journal-title":"Acta Biomater"},{"key":"361_CR75","doi-asserted-by":"publisher","unstructured":"Sarkar S, Greer J, Marlowe NJ, Medvid A, Ivan ME, Kolishetti N et al. Stemness, invasion, and immunosuppression modulation in recurrent glioblastoma using nanotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Jul-Aug;16(4):e1976. https:\/\/doi.org\/10.1002\/wnan.1976","DOI":"10.1002\/wnan.1976"},{"issue":"1","key":"361_CR76","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13578-024-01332-3","volume":"14","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu Z, Wei Y, He S, Gu A, Li Z, et al. Single-cell multi-omics analysis reveals candidate therapeutic drugs and key transcription factor specifically for the mesenchymal subtype of glioblastoma. Cell Biosci. 2024;14(1):151. https:\/\/doi.org\/10.1186\/s13578-024-01332-3.","journal-title":"Cell Biosci"},{"issue":"4","key":"361_CR77","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.humimm.2020.12.005","volume":"82","author":"A Churov","year":"2021","unstructured":"Churov A, Zhulai G. Targeting adenosine and regulatory T cells in cancer immunotherapy. Hum Immunol. 2021;82(4):270\u20138. https:\/\/doi.org\/10.1016\/j.humimm.2020.12.005.","journal-title":"Hum Immunol"},{"issue":"5","key":"361_CR78","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. LAG-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.001.","journal-title":"Immunity"},{"issue":"8","key":"361_CR79","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"key":"361_CR80","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","volume":"6","author":"RD Leone","year":"2018","unstructured":"Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6:57. https:\/\/doi.org\/10.1186\/s40425-018-0360-8.","journal-title":"J Immunother Cancer"},{"key":"361_CR81","doi-asserted-by":"publisher","first-page":"837230","DOI":"10.3389\/fimmu.2022.837230","volume":"13","author":"C Sun","year":"2022","unstructured":"Sun C, Wang B, Hao S. Adenosine-A2A receptor pathway in Cancer immunotherapy. Front Immunol. 2022;13:837230. https:\/\/doi.org\/10.3389\/fimmu.2022.837230.","journal-title":"Front Immunol"},{"issue":"1","key":"361_CR82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","volume":"26","author":"S Goswami","year":"2020","unstructured":"Goswami S, Walle T, Cornish AE, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020;26(1):39\u201346. https:\/\/doi.org\/10.1038\/s41591-019-0694-x.","journal-title":"Nat Med"},{"issue":"22","key":"361_CR83","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1523\/JNEUROSCI.1118-18.2019","volume":"39","author":"A Yan","year":"2019","unstructured":"Yan A, Joachims ML, Thompson LF, Miller AD, Canoll PD, Bynoe MS. CD73 promotes glioblastoma pathogenesis and enhances its chemoresistance via A\u2082B adenosine receptor signaling. J Neurosci. 2019;39(22):4387\u2013402. https:\/\/doi.org\/10.1523\/JNEUROSCI.1118-18.2019.","journal-title":"J Neurosci"},{"key":"361_CR84","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41419-021-04359-3","volume":"12","author":"M Wang","year":"2021","unstructured":"Wang M, Jia J, Cui Y, Peng Y, Jiang Y. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion. Cell Death Dis. 2021;12:1065. https:\/\/doi.org\/10.1038\/s41419-021-04359-3.","journal-title":"Cell Death Dis"},{"issue":"1","key":"361_CR85","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","volume":"10","author":"L Fong","year":"2020","unstructured":"Fong L, Hotson A, Powderly JD, et al. Adenosine A2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discov. 2020;10(1):40\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0980.","journal-title":"Cancer Discov"},{"key":"361_CR86","doi-asserted-by":"publisher","unstructured":"Bendell JC, O\u2019Neil BH, Bendell R et al. First-in-human study of oleclumab (MEDI9447), an anti-CD73 mAb, alone or with durvalumab in advanced solid tumors. Cancer Immunol Immunother \/ Tumour Biol (first-in-human report published via Springer).* 2023. https:\/\/doi.org\/10.1007\/s00262-023-03430-6","DOI":"10.1007\/s00262-023-03430-6"},{"issue":"1","key":"361_CR87","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al. RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"issue":"6","key":"361_CR88","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/10409238.2014.953627","volume":"49","author":"GG Yegutkin","year":"2014","unstructured":"Yegutkin GG. Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities. Crit Rev Biochem Mol Biol. 2014;49(6):473\u201397. https:\/\/doi.org\/10.3109\/10409238.2014.953627.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"361_CR89","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","volume":"10","author":"S Vigano","year":"2019","unstructured":"Vigano S, Alatzoglou D, Irving M, et al. Targeting adenosine in cancer immunotherapy to enhance T-cell function. Front Immunol. 2019;10:925. https:\/\/doi.org\/10.3389\/fimmu.2019.00925.","journal-title":"Front Immunol"},{"key":"361_CR90","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-3-030-47189-7_9","volume":"1270","author":"L Antonioli","year":"2021","unstructured":"Antonioli L, Fornai M, Pellegrini C, D\u2019Antongiovanni V, Turiello R, Morello S, Blandizzi C, Pacher P, Hask\u00f3 G. Adenosine signaling in the tumor microenvironment. Adv Exp Med Biol. 2021;1270:145\u201367. https:\/\/doi.org\/10.1007\/978-3-030-47189-7_9.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"361_CR91","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","volume":"67","author":"RD Leone","year":"2018","unstructured":"Leone RD, Sun IM, Oh MH, et al. Inhibition of the adenosine A2A receptor modulates expression of T-cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol Immunother. 2018;67(8):1271\u201384. https:\/\/doi.org\/10.1007\/s00262-018-2186-0.","journal-title":"Cancer Immunol Immunother"},{"key":"361_CR92","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","volume":"53","author":"M Roh","year":"2020","unstructured":"Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B. Targeting CD73 to augment cancer immunotherapy. Curr Opin Pharmacol. 2020;53:66\u201376. https:\/\/doi.org\/10.1016\/j.coph.2020.07.001.","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"361_CR93","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2019","unstructured":"Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2019;20(1):12\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0224-7.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"361_CR94","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1515\/cclm-2019-0858","volume":"58","author":"K \u0160\u010dup\u00e1kov\u00e1","year":"2020","unstructured":"\u0160\u010dup\u00e1kov\u00e1 K, Balluff B, Tressler C, et al. Cellular resolution in clinical MALDI mass spectrometry imaging: the latest advancements and current challenges. Clin Chem Lab Med. 2020;58(6):914\u201329. https:\/\/doi.org\/10.1515\/cclm-2019-0858.","journal-title":"Clin Chem Lab Med"},{"key":"361_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcdb.2024.12.006","volume":"167","author":"JR Whittle","year":"2025","unstructured":"Whittle JR, Kriel J, Fatunla OE, Lu T, Moffet JJD, Spiteri M, Best SA, Freytag S. Spatial omics shed light on the tumour organisation of glioblastoma. Semin Cell Dev Biol. 2025;167:1\u20139. https:\/\/doi.org\/10.1016\/j.semcdb.2024.12.006.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"361_CR96","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","volume":"180","author":"F Jacob","year":"2020","unstructured":"Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020;180(1):188\u2013e20422. https:\/\/doi.org\/10.1016\/j.cell.2019.11.036.","journal-title":"Cell"},{"key":"361_CR97","doi-asserted-by":"publisher","first-page":"599857","DOI":"10.3389\/fphar.2020.599857","volume":"11","author":"MJ Sun","year":"2020","unstructured":"Sun MJ, Liu F, Zhao YF, Wu XA. In vivo positron emission tomography imaging of adenosine A2A receptors. Front Pharmacol. 2020;11:599857. https:\/\/doi.org\/10.3389\/fphar.2020.599857.","journal-title":"Front Pharmacol"},{"issue":"3","key":"361_CR98","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov EN, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320. https:\/\/doi.org\/10.1016\/j.it.2016.01.004.","journal-title":"Trends Immunol"},{"issue":"3","key":"361_CR99","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127(3):929\u201341. https:\/\/doi.org\/10.1172\/JCI89455.","journal-title":"J Clin Invest"},{"key":"361_CR100","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1038\/s41467-022-33053-1","volume":"13","author":"VM Ravi","year":"2022","unstructured":"Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Sali\u00e9 H, et al. Spatially resolved multi-omics decodes the interplay between the immune microenvironment and GBM cells. Nat Commun. 2022;13:5355. https:\/\/doi.org\/10.1038\/s41467-022-33053-1.","journal-title":"Nat Commun"},{"issue":"3","key":"361_CR101","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477\u201386. https:\/\/doi.org\/10.1038\/s41591-018-0337-7.","journal-title":"Nat Med"},{"issue":"1","key":"361_CR102","doi-asserted-by":"publisher","first-page":"e154949","DOI":"10.1172\/JCI154949","volume":"132","author":"EE Wicks","year":"2022","unstructured":"Wicks EE, Semenza GL. Hypoxia-inducible factors: Cancer progression and clinical translation. J Clin Invest. 2022;132(1):e154949. https:\/\/doi.org\/10.1172\/JCI154949.","journal-title":"J Clin Invest"},{"issue":"4","key":"361_CR103","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178(4):835\u2013e84921. https:\/\/doi.org\/10.1016\/j.cell.2019.06.024.","journal-title":"Cell"},{"issue":"4","key":"361_CR104","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nm.3488","volume":"20","author":"M Angelo","year":"2014","unstructured":"Angelo M, Bendall SC, Finck R, Hale MB, Hitzman C, Borowsky AD, Levenson RM, Lowe JB, Liu SD, Zhao S, Natkunam Y, Nolan GP. Multiplexed ion beam imaging of human breast tumors. Nat Med. 2014;20(4):436\u201342. https:\/\/doi.org\/10.1038\/nm.3488.","journal-title":"Nat Med"},{"issue":"12","key":"361_CR105","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/0008-5472.CAN-20-4026","volume":"81","author":"M Gr\u00f6nholm","year":"2021","unstructured":"Gr\u00f6nholm M, Feodoroff M, Antignani G, Martins B, Hamdan F, Cerullo V. Patient-derived organoids for precision cancer immunotherapy. Cancer Res. 2021;81(12):3149\u201355. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-4026.","journal-title":"Cancer Res"},{"issue":"2","key":"361_CR106","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A L\u00f3pez-Soto","year":"2017","unstructured":"L\u00f3pez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell. 2017;32(2):135\u201354. https:\/\/doi.org\/10.1016\/j.ccell.2017.06.009.","journal-title":"Cancer Cell"},{"issue":"1","key":"361_CR107","doi-asserted-by":"publisher","first-page":"8260","DOI":"10.1038\/s41467-023-43917-5","volume":"14","author":"T Hu","year":"2023","unstructured":"Hu T, Allam M, Cai S, Henderson W, Yueh B, Garipcan A, Ievlev AV, Afkarian M, Beyaz S, Coskun AF. Single-cell spatial metabolomics with cell-type specific protein profiling for tissue systems biology. Nat Commun. 2023;14(1):8260. https:\/\/doi.org\/10.1038\/s41467-023-43917-5.","journal-title":"Nat Commun"},{"issue":"8","key":"361_CR108","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41587-019-0206-z","volume":"37","author":"AT Satpathy","year":"2019","unstructured":"Satpathy AT, Granja JM, Yost KE, Qi Y, Meschi F, McDermott GP, et al. Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. Nat Biotechnol. 2019;37(8):925\u201336. https:\/\/doi.org\/10.1038\/s41587-019-0206-z.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"361_CR109","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12(1):81. https:\/\/doi.org\/10.1186\/s13287-020-02128-1.","journal-title":"Stem Cell Res Ther"},{"key":"361_CR110","doi-asserted-by":"publisher","first-page":"829509","DOI":"10.3389\/fbioe.2022.829509","volume":"10","author":"MM Smit","year":"2022","unstructured":"Smit MM, Feller KJ, You L, Storteboom J, Begce Y, Beerens C, et al. Spatially annotated single-cell sequencing for unraveling intratumor heterogeneity. Front Bioeng Biotechnol. 2022;10:829509. https:\/\/doi.org\/10.3389\/fbioe.2022.829509.","journal-title":"Front Bioeng Biotechnol"},{"issue":"399","key":"361_CR111","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","journal-title":"Sci Transl Med"},{"key":"361_CR112","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41467-020-14642-0","volume":"11","author":"K Aslan","year":"2020","unstructured":"Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, N\u00fa\u00f1ez NG, et al. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun. 2020;11:931. https:\/\/doi.org\/10.1038\/s41467-020-14642-0.","journal-title":"Nat Commun"},{"issue":"10","key":"361_CR113","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41592-024-02392-6","volume":"21","author":"JB Nunes","year":"2024","unstructured":"Nunes JB, Ijsselsteijn ME, Abdelaal T, Ursem R, van der Ploeg M, Giera M, et al. Integration of mass cytometry and mass spectrometry imaging for spatially resolved single-cell metabolic profiling. Nat Methods. 2024;21(10):1796\u2013800. https:\/\/doi.org\/10.1038\/s41592-024-02392-6.","journal-title":"Nat Methods"},{"key":"361_CR114","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12929-022-00879-y","volume":"29","author":"WC Hsieh","year":"2022","unstructured":"Hsieh WC, Budiarto BR, Wang YF, Lin CY, Gwo MC, So DK, et al. Spatial multi-omics analyses of the tumor immune microenvironment. J Biomed Sci. 2022;29:96. https:\/\/doi.org\/10.1186\/s12929-022-00879-y.","journal-title":"J Biomed Sci"},{"key":"361_CR115","doi-asserted-by":"publisher","first-page":"156163","DOI":"10.1016\/j.prp.2025.156163","volume":"274","author":"K Ghasemi","year":"2025","unstructured":"Ghasemi K, Targeting. LAG-3: Relatlimab, Fianlimab, and Ieramilimab reshape the landscape of cancer combination immunotherapy. Pathol Res Pract. 2025;274:156163. https:\/\/doi.org\/10.1016\/j.prp.2025.156163.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"361_CR116","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/cancers13020229","volume":"13","author":"K Jin","year":"2021","unstructured":"Jin K, Mao C, Chen L, Wang L, Liu Y, Yuan J. Adenosinergic pathway: a hope in the immunotherapy of glioblastoma. Cancers (Basel). 2021;13(2):229. https:\/\/doi.org\/10.3390\/cancers13020229.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"361_CR117","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1021\/acs.jmedchem.4c02151","volume":"68","author":"C Bi","year":"2025","unstructured":"Bi C, Patel JS, Liang SH. Development of CD73 inhibitors in tumor immunotherapy and opportunities in imaging and combination therapy. J Med Chem. 2025;68(7):6860\u20139. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02151.","journal-title":"J Med Chem"},{"issue":"12","key":"361_CR118","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3390\/brainsci14121286","volume":"14","author":"JLB Sim\u00f5es","year":"2024","unstructured":"Sim\u00f5es JLB, Braga GC, Fontana M, Assmann CE, Bagatini MD. The neuroprotective role of A2A adenosine purinoceptor modulation as a strategy against glioblastoma. Brain Sci. 2024;14(12):1286. https:\/\/doi.org\/10.3390\/brainsci14121286.","journal-title":"Brain Sci"},{"key":"361_CR119","doi-asserted-by":"publisher","first-page":"e13111","DOI":"10.1111\/bpa.13111","volume":"33","author":"SA Petterson","year":"2023","unstructured":"Petterson SA, S\u00f8rensen MD, Burton M, Thomassen M, Kruse TA, Michaelsen SR, et al. Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas. Brain Pathol. 2023;33:e13111. https:\/\/doi.org\/10.1111\/bpa.13111.","journal-title":"Brain Pathol"},{"issue":"Suppl 4","key":"361_CR120","doi-asserted-by":"publisher","first-page":"iv32","DOI":"10.1093\/noajnl\/vdaf104","volume":"7","author":"AP Landry","year":"2025","unstructured":"Landry AP, Ellenbogen Y, Ajisebutu A, Gui C, Gao A, Nassiri F, Zadeh G. Biomarkers of immunotherapy response in neuro-oncology. Neurooncol Adv. 2025;7(Suppl 4):iv32\u201340. https:\/\/doi.org\/10.1093\/noajnl\/vdaf104.","journal-title":"Neurooncol Adv"},{"issue":"2","key":"361_CR121","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics. 2017;14(2):307\u201320. https:\/\/doi.org\/10.1007\/s13311-016-0507-6.","journal-title":"Neurotherapeutics"},{"issue":"7","key":"361_CR122","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/cancers16071276","volume":"16","author":"I Salvato","year":"2024","unstructured":"Salvato I, Marchini A. Immunotherapeutic strategies for the treatment of glioblastoma: current challenges and future perspectives. Cancers (Basel). 2024;16(7):1276. https:\/\/doi.org\/10.3390\/cancers16071276.","journal-title":"Cancers (Basel)"},{"issue":"20","key":"361_CR123","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3390\/cells14201585","volume":"14","author":"V Salmaso","year":"2025","unstructured":"Salmaso V, Menin S, Moro S, Spalluto G, Federico S. Adenosine receptors in neuroinflammation and neurodegeneration. Cells. 2025;14(20):1585. https:\/\/doi.org\/10.3390\/cells14201585.","journal-title":"Cells"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00361-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00361-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00361-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:47:28Z","timestamp":1786430848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00361-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00361-y","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article has been updated to include author's ORCID ID 0009-0001-6038-7337.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by the author. Therefore, ethical approval was not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"21"}}